文献速递淋巴瘤

抗病毒预防改善台湾弥漫大B细胞淋巴瘤乙肝携带者预后

Antiviral prophylaxis for hepatitis B carriers improves the prognosis of diffuse large B-cell lymphoma in Taiwan - a population-based study.
PubMed 文献 · Br J Haematol · 2020-10-31

这项基于台湾癌症登记库的人群研究纳入2011至2015年接受R-CHOP、R-CVP、CHOP或CVP方案的新诊断成人DLBCL患者3702例。结果表明抗病毒预防可改善HBsAg阳性DLBCL患者的总生存。

要点

  • HBsAg阳性DLBCL患者接受抗病毒预防后中位OS与HBsAg阴性者相似。
  • HBV状态及抗病毒预防是多因素分析中的独立预后因素。

核心结论

  • 在HBsAg阳性DLBCL患者中,抗病毒预防可改善总生存,使其生存与HBV阴性患者相当。

研究设计与样本

  • 基于台湾癌症登记库的人群研究,纳入2011至2015年新诊断成人DLBCL患者3702例,均接受R-CHOP、R-CVP、CHOP或CVP方案。
  • 患者分为三组:HBsAg阴性组2921例、HBV携带者接受抗病毒预防组711例、HBV携带者未接受抗病毒预防组70例。

主要发现

  • 多因素分析显示HBV状态及抗病毒预防是独立预后因素。

临床怎么用

  • 对HBsAg阳性DLBCL患者在接受利妥昔单抗为基础的治疗时,应进行抗病毒预防以改善生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prevention of hepatitis B virus (HBV) reactivation during rituximab treatment for diffuse large B-cell lymphoma (DLBCL) is important in the HBV-endemic area. This population-based study examines the impact of antiviral prophylaxis for DLBCL patients with HBV infections. We identified 3702 adult patients with newly diagnosed DLBCL between 2011 and 2015 receiving R-CHOP, R-CVP, CHOP or CVP from the Taiwan Cancer Registry. We further stratified them into three groups: HBsAg-negative patients (HBV-negative, N = 2921), HBV carriers who received antiviral prophylaxis (HBV + Px, N = 711), and HBV carriers who did not receive antiviral prophylaxis (HBV + No Px, N = 70). HBV + Px patients were the youngest, and 69·4% received entecavir for antiviral prophylaxis. The median overall survival (mOS) of HBV-negative and HBV + Px patients was similar (74·23 months and not reached, respectively). However, the mOS of HBV + No Px patients was only 35·61 months (P = 0·0028 compared with HBV + Px patients), indicating that antiviral prophylaxis improves OS in HBsAg-positive DLBCL patients. The multivariate analysis showed that the HBV status and antiviral prophylaxis was an independent prognostic factor. In conclusion, our population-based study illustrates the importance of antiviral prophylaxis in HBsAg-positive DLBCL patients. Under antiviral prophylaxis, the survival of DLBCL patients with HBV infections was comparable to that of HBV-negative patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Huang HH, Hsiao FY, Chen HM, et al. Antiviral prophylaxis for hepatitis B carriers improves the prognosis of diffuse large B-cell lymphoma in Taiwan - a population-based study. Br J Haematol. 2020. PMID: 33131074. doi:10.1111/bjh.17142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。